- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Retrospective, Multicentre
- Study aim: To compare the effectiveness of molnupiravir, nirmatrelvir/ritonavir, and sotrovimab with no treatment in preventing hospital admission or death in higher-risk patients infected with SARS-CoV-2 in the community. It also aims to assess the risk of hospitalisation or death within 28 days for patients receiving different treatments and those with varying comorbidity levels
- Number of participants enrolled: 7013
- Study enrolling from to
- Study includes follow-up for 4 weeks
Study Data
- Adults
- Elderly
- Fragile population
- Outpatient clinic
- Non-hospital health centre
- Community
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
External Links
Other information
Funders:
- Health and Care Research Wales
- Medical Research Council
- UK Medical Research Council
- Engineering and Physical Sciences Research Council
- Economic and Social Research Council
- Department of Health and Social Care (England)
- Chief Scientist Office of the Scottish Government Health and Social Care Directorates
- Health and Social Care Research and Development Division (Welsh Government)
- Public Health Agency (Northern Ireland)
- British Heart Foundation (BHF)
- Wellcome Trust
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to